MOLBIO DIAGNOSTICS LTD

Makes Truenat, a point-of-care molecular diagnostics platform — bench-top hardware paired with single-test PCR cartridges for infectious diseases such as tuberculosis — with a global installed base and WHO endorsement for TB diagnosis at the point of care. Revenue comes mainly from recurring test-kit consumables (~75% of revenue), with hardware placements accounting for the balance; FY27 topline is guided at ~25% growth and EBITDA margin at 24–25%. Q1 FY27 consolidated revenue was ₹408 cr (including ₹67 cr of exports), EBITDA ₹104 cr at 25% margin, and PAT ₹52.7 cr. Two subsidiaries extend into adjacent imaging: OptraScan (60% stake, digital pathology, US FDA-cleared July 2026, loss-making in FY27) and Prognosys (70% stake, digital X-ray). R&D runs at 5–6% of revenue, supported by 153 scientists and a pipeline of 34 assays across 22 diseases; HPV testing awaits rollout under the Government of India programme.